CA2176259A1 - Composes oligonucleosidiques chimeriques - Google Patents

Composes oligonucleosidiques chimeriques

Info

Publication number
CA2176259A1
CA2176259A1 CA002176259A CA2176259A CA2176259A1 CA 2176259 A1 CA2176259 A1 CA 2176259A1 CA 002176259 A CA002176259 A CA 002176259A CA 2176259 A CA2176259 A CA 2176259A CA 2176259 A1 CA2176259 A1 CA 2176259A1
Authority
CA
Canada
Prior art keywords
rnaseh
linkage
compound
linkages
activating region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002176259A
Other languages
English (en)
Inventor
Lyle J. Arnold, Jr.
Mark A. Reynolds
Cristina Giachetti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genta Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2176259A1 publication Critical patent/CA2176259A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composés oligonucléosidiques chimériques et leurs procédés de préparation et de formulation. Ces composés et compositions sont utilisables dans l'activation du clivage à médiation par RNaseH des séquences cibles d'acide ribonucléique, et dans le traitement des états pathologiques associés à ces séquences.
CA002176259A 1993-11-16 1994-11-16 Composes oligonucleosidiques chimeriques Abandoned CA2176259A1 (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US15401393A 1993-11-16 1993-11-16
US15401493A 1993-11-16 1993-11-16
US08/154,013 1993-11-16
US08/154,014 1993-11-16
US08/223,778 1994-04-06
US23377894A 1994-04-26 1994-04-26
US23817794A 1994-05-04 1994-05-04
US08/238,177 1994-05-04
PCT/US1994/013387 WO1995013834A1 (fr) 1993-11-16 1994-11-16 Composes oligonucleosidiques chimeriques

Publications (1)

Publication Number Publication Date
CA2176259A1 true CA2176259A1 (fr) 1995-05-26

Family

ID=27496113

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002176259A Abandoned CA2176259A1 (fr) 1993-11-16 1994-11-16 Composes oligonucleosidiques chimeriques

Country Status (8)

Country Link
EP (1) EP0743859A4 (fr)
JP (1) JPH09506248A (fr)
KR (1) KR960705589A (fr)
AU (1) AU689182B2 (fr)
CA (1) CA2176259A1 (fr)
IL (1) IL111660A (fr)
NZ (1) NZ277617A (fr)
WO (1) WO1995013834A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5325696A (en) * 1995-04-03 1996-10-23 Hybridon, Inc. Method of modulating gene expression without depleting compl ement
US6509149B2 (en) * 1995-06-06 2003-01-21 Hybridon, Inc. HPV-specific oligonucleotides
US5898031A (en) * 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
AU3465599A (en) * 1998-04-01 1999-10-18 Hybridon, Inc. Mixed-backbone oligonucleotides containing pops blocks to obtain reduced phosphorothioate content
US6277967B1 (en) * 1998-07-14 2001-08-21 Isis Pharmaceuticals, Inc. Carbohydrate or 2′-modified oligonucleotides having alternating internucleoside linkages
EP2796553B1 (fr) † 2000-03-30 2019-06-19 Whitehead Institute for Biomedical Research Médiateurs spécifiques de la séquence d'ARN d'interférence d'ARN
ES2336887T5 (es) 2000-03-30 2019-03-06 Whitehead Inst Biomedical Res Mediadores de interferencia por ARN específicos de secuencias de ARN
CA2429814C (fr) 2000-12-01 2014-02-18 Thomas Tuschl Petites molecules d'arn mediant l'interference arn
DE60310944T3 (de) 2002-08-05 2017-08-03 Silence Therapeutics Gmbh Weitere neue formen von interferierende rns moleküle
TR201816291T4 (tr) * 2002-08-05 2018-11-21 Silence Therapeutics Gmbh Müdahaleci rna moleküllerinin ilave yeni biçimleri.
US9150606B2 (en) 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
US9150605B2 (en) 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
US9827263B2 (en) 2002-11-05 2017-11-28 Ionis Pharmaceuticals, Inc. 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations
US10202599B2 (en) * 2011-08-11 2019-02-12 Ionis Pharmaceuticals, Inc. Selective antisense compounds and uses thereof
WO2018051762A1 (fr) * 2016-09-14 2018-03-22 レナセラピューティクス株式会社 Oligonucléotide antisens à effets secondaires réduits
CA3151789A1 (fr) * 2019-09-19 2021-03-25 Arnay Sciences, Llc Composes et procedes utiles pour moduler l'epissage de genes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5212295A (en) * 1990-01-11 1993-05-18 Isis Pharmaceuticals Monomers for preparation of oligonucleotides having chiral phosphorus linkages
US5149797A (en) * 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
JP3131222B2 (ja) * 1991-12-24 2001-01-31 アイシス・ファーマシューティカルス・インコーポレーテッド ギャップを有する２′修飾オリゴヌクレオチド

Also Published As

Publication number Publication date
WO1995013834A1 (fr) 1995-05-26
AU689182B2 (en) 1998-03-26
JPH09506248A (ja) 1997-06-24
KR960705589A (ko) 1996-11-08
AU1291695A (en) 1995-06-06
EP0743859A1 (fr) 1996-11-27
IL111660A0 (en) 1995-01-24
IL111660A (en) 2005-05-17
EP0743859A4 (fr) 1998-10-21
NZ277617A (en) 1998-01-26

Similar Documents

Publication Publication Date Title
US6060456A (en) Chimeric oligonucleoside compounds
AU2003202376B2 (en) Oligonucleotides comprising alternating segments and uses thereof
US6028188A (en) Synthetic oligomers having chirally pure phosphonate internucleosidyl linkages mixed with non-phosphonate internucleosidyl linkages
US5986083A (en) Synthetic oligomers having phosphonate internucleosidyl linkages of undefined chirality mixed with non-phosphonate internucleosidyl linkages
US6015886A (en) Oligonucleotide phosphate esters
AU678769B2 (en) Oligonucleotide alkylphosphonothioates
AU2003202376A1 (en) Oligonucleotides comprising alternating segments and uses thereof
US20030083477A1 (en) Three component chimeric antisense oligonucleotides
CA2176259A1 (fr) Composes oligonucleosidiques chimeriques
JPH06511155A (ja) ギャップを有する２′修飾オリゴヌクレオチド
Miller Non-ionic antisense oligonucleotides
US8178348B2 (en) Chimeric antisense oligonucleotides of arabinofuranose analogue and deoxyribose nucleotides
JPH07508657A (ja) ｒａｓ遺伝子のアンチセンスオリゴヌクレオチドによる阻害
Noe et al. Chemistry of antisense oligonucleotides

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued